NCT06934642

Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

Effect of Tirzepatide on Markers of MASLD in Patients With Obesity: A Pilot Study

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: University of New Mexico · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity. It has also been shown to help with MASLD. The purpose of this study is to study how tirzepatide affects the liver in patients with MASLD. Participants will be asked to: * Take tirzepatide for 12 months. * Come in for clinic visits every 3 months. * Have blood drawn at baseline, 6, and 12 months. * Complete a liver ultrasound at baseline and at 12 months.

Conditions

• MASLD
• Obesity

Interventions

Type	Name	Description
DRUG	Tirzepatide	The drug is being studied to better understand the biological effects of tirzepatide on MASLD.

Timeline

• Start date: 2025-06-30
• Primary completion: 2026-08-01
• Completion: 2026-08-01
• First posted: 2025-04-18
• Last updated: 2025-07-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study